16 (ON-BP),” American Journal of Hypertension, vol. 21, no. 11, pp. 1210–1215, 2008. [186] T. G. Pickering, J. E. Hall, L. J. Appel et al., “Recommen- dations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans—a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on high blood pressure research,” Circulation, vol. 111, no. 5, pp. 697–716, 2005. [187] M. Moser and J. F. Setaro, “Resistant or diﬃcult-to-control hypertension,” New England Journal of Medicine, vol. 355, no. 4, pp. 385–392, 2006. [188] D. A. Calhoun, D. Jones, S. Textor et al., “Resistant hyper- tension: diagnosis, evaluation, and treatment: a scientiﬁc statement from the American Heart Association Professional Education Committee of the Council for High Blood Pres- sure Research,” Circulation, vol. 117, pp. e510–e526, 2008. [189] P. A. Saraﬁdis and G. L. Bakris, “State of hypertension management in the United States: conﬂuence of risk factors and the prevalence of resistant hypertension,” Journal of Clinical Hypertension, vol. 10, no. 2, pp. 130–139, 2008. [190] J. Redon, C. Campos, M. L. Narciso, J. L. Rodicio, J. M. Pascual, and L. M. Ruilope, “Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study,” Hypertension, vol. 31, no. 2, pp. 712–718, 1998. [191] S. D. Pierdomenico, D. Lapenna, A. Bucci et al., “Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension,” American Journal of Hypertension, vol. 18, no. 11, pp. 1422–1428, 2005. [192] M. A. Brown, M. L. Buddle, and A. Martin, “Is resistant hypertension really resistant?” American Journal of Hypertension, vol. 14, no. 12, pp. 1263–1269, 2001. [193] M. K. Nishizaka, M. A. Zaman, D. A. Calhoun et al., “Eﬃcacy of low-dose spironolactone in subjects with resistant hypertension,” American Journal of Hypertension, vol. 16, no. 11, pp. 925–930, 2003. [194] E. Pimenta, K. K. Gaddam, S. Oparil et al., “Eﬀects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial,” Hypertension, vol. 54, no. 3, pp. 475–481, 2009. [195] L. E. Ramsay, J. H. Silas, and S. Freestone, “Diuretic treatment of resistant hypertension,” British Medical Journal, vol. 281, no. 6248, pp. 1101–1103, 1980. [196] J. Ouzan, C. Perault, A. M. Lincoﬀ, E. Carre´, and M. Mertes, “The role of spironolactone in the treatment of patients with refractory hypertension,” American Journal of Hypertension, vol. 15, no. 4, pp. 333–339, 2002. [197] A. Mahmud, M. Mahgoub, M. Hall, and J. Feely, “Does aldosterone-to-renin ratio predict the antihypertensive eﬀect of the aldosterone antagonist spironolactone?” American Journal of Hypertension, vol. 18, no. 12, pp. 1631–1635, 2005. [198] C. Saha, G. J. Eckert, W. T. Ambrosius et al., “Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension,” Hypertension, vol. 46, no. 3, pp. 481–487, 2005. [199] Y. Sharabi, E. Adler, A. Shamis, N. Nussinovitch, A. Markovitz, and E. Grossman, “Eﬃcacy of add-on aldosterone receptor blocker in uncontrolled hypertension,” American Journal of Hypertension, vol. 19, no. 7, pp. 750–755, 2006. International Journal of Hypertension [200] F. de Souza, E. Muxfeldt, R. Fiszman, and G. Salles, “Eﬃcacy of spironolactone therapy in patients with true resistant hypertension,” Hypertension, vol. 55, no. 1, pp. 147–152, 2010. [201] S. J. Hood, K. P. Taylor, M. J. Ashby, and M. J. Brown, “The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) double-blind crossover trial in patients with low- renin hypertension and elevated aldosterone-renin ratio,” Circulation, vol. 116, no. 3, pp. 268–275, 2007. [202] D. A. Lane, S. Shah, and D. G. Beevers, “Low-dose spironolactone in the management of resistant hypertension: a surveillance study,” Journal of Hypertension, vol. 25, no. 4, pp. 891–894, 2007. [203] N. Chapman, J. Dobson, S. Wilson et al., “Eﬀect of spirono- lactone on blood pressure in subjects with resistant hyperten- sion,” Hypertension, vol. 49, no. 4, pp. 839–845, 2007. [204] D. A. Lane and D. G. Beevers, “Amiloride 10 mg is less eﬀective than spironolactone 25 mg in patients with hypertension resistant to a multidrug regime including an angiotensin-blocking agent,” Journal of Hypertension, vol. 25, no. 12, pp. 2515–2516, 2007. [205] H. K. Parthasarathy, K. Alhashmi, A. D. McMahon et al., “Does the ratio of serum aldosterone to plasma renin activity predict the eﬃcacy of diuretics in hypertension? Results of RENALDO,” Journal of Hypertension, vol. 28, no. 1, pp. 170–177, 2010. [206] R. C. Hermida, D. E. Ayala, J. R. Fernandez, and C. Calvo, “Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension,” Hypertension, vol. 51, no. 1, pp. 69–76, 2008. [207] R. Minutolo, F. B. Gabbai, S. Borrelli et al., “Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial,” American Journal of Kidney Diseases, vol. 50, no. 6, pp. 908–917, 2007. [208] C. Tsiouﬁs, A. Kasiakogias, C. Thomopoulos, A. Manolis, and C. Stefanadis, “Managing hypertension in obstructive sleep apnea: the interplay of continuous positive airway pressure, medication and chronotherapy,” Journal of Hypertension, vol. 28, no. 5, pp. 875–882, 2010. [209] M. A. Weber, H. Black, G. Bakris et al., “A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial,” Lancet, vol. 374, no. 9699, pp. 1423–1431, 2009. [210] G. L. Bakris, L. H. Lindholm, H. R. Black et al., “Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial,” Hypertension, vol. 56, no. 5, pp. 824–830, 2010. [211] J. J. Oliver, J. W. Dear, and D. J. Webb, “Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension,” Hypertension, vol. 56, no. 1, pp. 62–67, 2010. [212] M. Doumas, D. Guo, and V. Papademetriou, “Carotid baroreceptor stimulation as a therapeutic target in hypertension and other cardiovascular conditions,” Expert Opinion on Therapeutic Targets, vol. 13, no. 4, pp. 413–425, 2009. [213] M. Doumas, C. Faselis, and V. Papademetriou, “Renal sym- pathetic denervation and systemic hypertension,” American Journal of Cardiology, vol. 105, no. 4, pp. 570–576, 2010.